EdgeMarket › What Cormorant Asset Management, Lp reported owning
What Cormorant Asset Management, Lp reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
2.0BPositions
47Quarter
2026-03-31Shown below
46largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| PRAX Praxis Precision Medicines, Inc. | 285.3M | 14.3% | 885.5K | 375.94 | +730.8% |
| BBOT BridgeBio Oncology Therapeutics, Inc. | 160.0M | 8.0% | 17.9M | 9.08 | -5.7% |
| EYPT EyePoint, Inc. | 106.5M | 5.4% | 8.3M | 5.32 | -53.8% |
| EWTX Edgewise Therapeutics, Inc. | 102.7M | 5.2% | 3.3M | 44.18 | +219.2% |
| ERAS Erasca, Inc. | 93.8M | 4.7% | 5.8M | 17.63 | +1107.5% |
| RAPP Rapport Therapeutics, Inc. | 92.5M | 4.6% | 3.0M | 48.24 | +236.9% |
| ALMS ALUMIS INC. | 87.0M | 4.4% | 3.9M | 24.17 | +448.1% |
| ABVX Abivax S.A. | 84.6M | 4.3% | 760.0K | 114.95 | +59.9% |
| MLTX MoonLake Immunotherapeutics | 83.5M | 4.2% | 4.5M | 15.76 | -70.9% |
| DNTH Dianthus Therapeutics, Inc. /DE/ | 79.7M | 4.0% | 950.0K | 111.10 | +374.4% |
| DRUG BRIGHT MINDS BIOSCIENCES INC. | 77.3M | 3.9% | 1.1M | 77.42 | +80.0% |
| BBIO BridgeBio Pharma, Inc. | 63.1M | 3.2% | 850.0K | 81.50 | +66.7% |
| OLMA Olema Pharmaceuticals, Inc. | 58.1M | 2.9% | 3.9M | 10.69 | +96.1% |
| BIOA BioAge Labs, Inc. | 50.6M | 2.5% | 2.9M | 9.48 | +113.5% |
| unmapped CUSIP 152309100 | 41.7M | 2.1% | 1.1M | — | — |
| DMRA Damora Therapeutics, Inc. | 39.5M | 2.0% | 1.5M | 30.82 | +811.9% |
| MBX MBX Biosciences, Inc. | 33.4M | 1.7% | 1.1M | 66.33 | +386.6% |
| INSM INSMED Inc | 31.1M | 1.6% | 190.0K | 125.77 | -2.8% |
| NAMS NewAmsterdam Pharma Co N.V. | 30.4M | 1.5% | 950.0K | 27.87 | +14.6% |
| TNGX Tango Therapeutics, Inc. | 29.8M | 1.5% | 1.4M | 23.88 | +253.8% |
| PHVS Pharvaris N.V. | 28.2M | 1.4% | 1.0M | 36.27 | +57.7% |
| ORKA Oruka Therapeutics, Inc. | 26.2M | 1.3% | 533.3K | 107.96 | +649.7% |
| AGMB Agomab Therapeutics NV | 25.9M | 1.3% | 2.5M | 13.25 | — |
| MAZE Maze Therapeutics, Inc. | 22.4M | 1.1% | 750.0K | 29.43 | +118.3% |
| CRBP Corbus Pharmaceuticals Holdings, Inc. | 22.0M | 1.1% | 2.3M | 10.38 | +12.6% |
| ASND Ascendis Pharma A/S | 21.7M | 1.1% | 95.0K | 253.29 | +31.4% |
| ROIV Roivant Sciences Ltd. | 20.8M | 1.0% | 750.0K | 36.30 | +209.7% |
| ANL Adlai Nortye Ltd. | 20.1M | 1.0% | 2.9M | 13.70 | +720.4% |
| unmapped CUSIP 880881107 | 15.8M | 0.8% | 300.0K | — | — |
| TARS Tarsus Pharmaceuticals, Inc. | 15.8M | 0.8% | 225.0K | 72.70 | +31.2% |
| BHVN Biohaven Ltd. | 14.9M | 0.7% | 1.8M | 13.85 | -5.8% |
| CABA Cabaletta Bio, Inc. | 14.8M | 0.7% | 5.5M | 3.13 | +98.1% |
| HLXC Helix Acquisition Corp. III | 13.2M | 0.7% | 1.3M | 10.93 | — |
| ARQT Arcutis Biotherapeutics, Inc. | 10.6M | 0.5% | 450.0K | 25.08 | +58.8% |
| FTH Faeth Therapeutics, Inc. | 9.7M | 0.5% | 306.2K | 32.00 | +302.1% |
| CRNX Crinetics Pharmaceuticals, Inc. | 9.1M | 0.5% | 250.0K | 84.69 | +191.1% |
| ZURA Zura Bio Ltd | 8.6M | 0.4% | 1.4M | 5.85 | +234.3% |
| AXSM Axsome Therapeutics, Inc. | 8.5M | 0.4% | 50.0K | 207.77 | +77.6% |
| GPCR Structure Therapeutics Inc. | 8.4M | 0.4% | 175.0K | 49.09 | +164.4% |
| COGT Cogent Biosciences, Inc. | 7.7M | 0.4% | 200.0K | 36.73 | +209.6% |
| GLUE Monte Rosa Therapeutics, Inc. | 6.6M | 0.3% | 400.0K | 14.30 | +222.8% |
| ARWR ARROWHEAD PHARMACEUTICALS, INC. | 6.3M | 0.3% | 100.0K | 87.11 | +331.2% |
| PCVX Vaxcyte, Inc. | 5.8M | 0.3% | 100.0K | 62.62 | +100.3% |
| AMLX Amylyx Pharmaceuticals, Inc. | 4.9M | 0.2% | 350.0K | 38.66 | +381.4% |
| RLYB Rallybio Corp | 3.6M | 0.2% | 400.0K | 16.83 | +247.0% |
| CNTX Context Therapeutics Inc. | 1.4M | 0.1% | 529.5K | 0.50 | -44.7% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →